8th Floor, Detech II Building, 107 Nguyen Phong Sac, Cau Giay District - Hanoi City.
Doctor
Dr Tony Roberts
MBBS, FRACP Endocrinology

Bác sĩ Roberts có một loạt trách nhiệm y tế, từ các cuộc hẹn trong các dịch vụ ngoại trú cho bệnh nhân tiểu đường, làm việc với Phòng Hóa học lâm sàng của I.M.V.S cũng như điều phối các dịch vụ Tiểu đường nói chung.

Ông có hơn 40 năm kinh nghiệm trong ngành y và đã tiến hành nghiên cứu đột phá về Bệnh tiểu đường và các vấn đề y tế khác từ năm 1974. Ông đã đóng góp và là tác giả của vô số bài báo và được mời phát biểu tại các sự kiện nổi tiếng thế giới như Tiểu đường Châu Á Thái Bình Dương Hội nghị thượng đỉnh lãnh đạo, Bắc Kinh 2008.

Bác sĩ Tony Roberts hiện là cố vấn cao cấp cho Đơn vị Nội tiết & Chuyển hóa và là điều phối viên cho Phòng khám Tuyến giáp và Tuyến cận giáp tại Bệnh viện Hoàng gia Adelaide.

Bác sĩ Roberts tham gia hành nghề tư nhân với tư cách là bác sĩ nội tiết và là nhà điều tra chính tại SA Endocrine Research Pty Ltd.

  • 1975: University of Adelaide, M.B.B.S
  • 1982: F.R.A.C.P

CURRENT APPOINTMENTS:

  • Senior Consultant – Endocrine & Metabolic Unit, Royal Adelaide Hospital, ADELAIDE
  • Coordinator – Thyroid and Parathyroid Clinic, Royal Adelaide Hospital, ADELAIDE
  • Consultant Endocrinologist – Private Practice, KESWICK SA
  • Principal Investigator – SA Endocrine Research Pty Ltd, KESWICK SA

FORMER APPOINTMENTS:

  • 1985 – 1997: Medical Coordinator – Diabetes Centre, Royal Adelaide Hospital
    ADELAIDE
  • 1985- 1997: Honorary Consultant – Endocrinologist Centre for Women & Children
    NORTH ADELAIDE
  • 1985 – 1997: Honorary Consultant – Endocrinologist, South Australian Sports Institute KIDMAN PARK
  • 1985 – 1994: Senior Visiting Consultant – Endocrinologist Diabetes Education Centre
    Lyell McEwin Health Service, ELIZABETH
  • 1990 – 1999: Consultant Endocrinologist – Osteoscan Pty Ltd (Bone Densitometry service) Ashford Specialist Centre ASHFORD
  • 1990 – 2001: Principal Investigator – Ashford International Research Centre (Ashford Specialist Centre)

 

 

  • Health Promotions Unit
  • Medical Records Committee
  • RAH Library Committee – Chair
  • Royal Australasian College of Physicians
  • Endocrine Society of Australia
  • Australian Diabetes Society
  • Australian Diabetes Educators Association
  • Adelaide Clinical Endocrine Society
  • South Australian Salaried Medical Officers Association
  • Australian Doctors Fund
  • Australian Medical Association
  • Osteoporosis S.A.
  • Diabetes Australia – SA
  • Australian Menopause Society
  • Australian & New Zealand Bone & Mineral Society
  • Australian & New Zealand Obesity Society
  • Australian & New Zealand Professional Association for Transgender Health
  • Australian Pituitary Foundation
  • Australian Thyroid Foundation
  • University of Adelaide Alumni
  • American Diabetes Association
  • International Bone Densitometry Society
  • International Bone & Mineral Society
  • International Diabetes Federation
  • International Osteoporosis Foundation
  • National Osteoporosis Foundation (USA)
  • National Osteoporosis Society (United Kingdom)
  • The World Professional Association for Transgender Health
  1. Wilson, L., Roberts, A., O’Halloran, M. Twice daily methyldopa: Home blood
    pressure recordings. Med.J. Aust 1979; 2: 263
  2. Roberts, A.P., Story, C.J. and Ryall, R.G. Erythrocyte 2,3- bisphosphoglycerate
    concentrations and haemoglobin glycosylation in normoxic insulin dependant
    diabetes mellitus. Diabetologia 1984; 26:389
  3. Story, C.J., Roberts, A.P. and Ryall, R.G. Borderline maintenance of erythrocyte
    2, 3-diphosphoglycerate concentrations in normoxic Type I diabetic subject. Clinc.
    Science 1985, 69:106
  4. Horowitz, M., and Roberts, A.P., Long term efficacy of Cisapride in diabetes
    gastroproesis. AM J Med 1990;89:195
  5. Westerman, R. Delaney, C., Ivamy-Philips, A., Horowitz, M., and Roberts, A.P.
    Concordance between different measures of small sensory and autonomic fibre
    neuropathy, in diabetes mellitus. Clinical and Experimental Neurology 1989; 26
    51-63
  6. Roberts A.P. Initiation of insulin therapy in a patient with insulin dependant
    diabetes mellitus. Diabetes 1995 1;4:
  7. Taggart H, Bolognese M, Lindsay R, Ettinger M.P., Mulder H, Josse R.G, Roberts
    A, Zippel H, Adami S, Ernst T and Stevens K. P. Upper gastrointestinal Safety
    Profile of Risedronate in the Treatment and Prevention of Postmenopausal and
    Glucocorticoid-Induced Osteoporosis. Submitted 2001.
  8. Worthley D.L., Harvey N.T, Hill N.L., Walsh R.L., Edwards J.B. and Roberts A P.
    Urinary transferrin and albumin concentrations in patients with Type I diabetes and
    normal controls: The search for the first protein lost. Clinical Biochemistry 2001;
    34: 83-85
  9. Roberts A P. Inhaled Insulin – work in progress, Diabetes Management Journal
    2005; 11:8
  10. Standl E, Lang H. Comparison of the Long-term Safety & Efficacy of Insulin
    Detemir and NPH insulin showed favourable weight reduction for insulin Detemir
    in subjects with Type I diabetes on a basal-bolus regimen and with meal related
    human soluble insulin. Diabetes Core (submitted).
  11. Benedikt Greutelaers, Katrin Kulen, Peter Malycha, James Kollias, Melissa
    Bochner, Anthony Roberts, Garry Wittert Janice Pasieka. The PASIEKA Illness
    Questionnaire: its value in primary hyperparathyroidism.
  12. Kennedy RJ, Roberts A P, Reece GH, Malycha PL. Minimally Invasive
    Parathyroidectomy for recurrent or persistent hyperparathyroidism using carbon
    track localisation. Aust. NZ Journey Surgery: 2003.
  13. Eberhard Standl, Hanne Lang, Anthony Roberts. The 12-month efficacy and
    safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment
    of type 1 diabetes. Diabetes Technology & Therapeutics (submitted).
    Curriculum Vitae Dr Anthony Philip Roberts
  14. David M. Kendall, MD, Cindy J. Rubin, MD, Pharis Mohideen, MD, Jean-Marie
    Ledeine, MSC, Rene Belder, MD, Jorge Gross, MD, Paul Norwood, MD, Michael
    O’Mahony, MD, Kenneth Sall, MD, Greg Sloan, MD, Anthony Roberts, MBBS, Fred
    T Fiedorek, MD and Ralph A. DeFronzo. Improvement of glycaemic control,
    Triglycerides and HDL-C Levels with Muraglitazar, a dual (a/g) PPAR Activator in
    Patients with Type 2 Diabetes Inadequately Controlled with Metformin
    Monotherapy: A double-blind, randomized, Pioglitazone-comparative study.
    Diabetes Care: in press.
  15. Hugh Taggart, MD; Michael A. Bolognese, MD; Robert Lindsay, MD, PhD; Mark P.
    Ettinger, MD; Henk Mulder, MD, PhD; Robert G Josse, MBBS; Anthony Roberts,
    MBBS; Hartmut Zippel, MD; Silvano Adami, MD; Teresa F. Ernst, PharmD; Karen
    P. Stevens, PharmD; on behalf of the risedronate clinical study investigators.
    Upper Gastrointestinal Safety of Risedronate: A Pooled Analysis of Nine Clinical
    Trials. Mayo Clinic Proceedings (submitted)
  16. M. J. Hooper, P. R. Ebeling, A. P. Roberts, J. J. Graham, G. C. Nicholson, M.
    D’Emden, T. F, Ernst and D. Wenderoth. Risedronate prevents bone loss in early
    postmenopausal women: a prospective randomised, placebo-controlled trial.
    Climacteric 2005.
  17. Barnett A, Kendall D, Johns Jr D, Burger J, Trauntmann M, Brodows R, Roberts
    A. Tolerability and efficacy of Exenatide and titrated insulin Glargine in Adults.
    patients with Type 2 diabetes previously uncontrolled with Metformin or a
    Sulphonylurea, a multinational, randomised open label, two period, cross over,
    non-interiority trial. Clin. Therapeutics on-line. 2007
  18. Carter J and Roberts A. The usability of a pre-filled insulin injection device in a 3
    month observational survey of everyday clinical practice in Australia. Results of
    telephone interviews with Health Care Professionals and people with Diabetes.
    Curr Med. Res. Opinion. Submitted 2008.
  19. Reginster J Y, Bruyere O, Sawicki A et al. Long-term treatment of postmenopausal
    osteoporosis with strontium ranelate: Results at 8 years. Bone 2009; 45: 1059-
    1064
  20. Meneghini L, Home P, Wendisch U et al. Insulin Degludec, a new generation ultralong-
    acting insulin in a mealtime + basal regimen in people with Type 1 diabetes.
    Diabetes Care 2011; 34: 661-665.
  21. Gregory Fulcher, Anthony Roberts Snr Consultant RAH, Ashim Sinha, Joseph
    Proietto. What happens when patients require intensification from basal insulin? A
    retrospective audit of clinical practice for the treatment of type 2 diabetes from four
    Australian centres. Diabetes Research and Clinical Practice, Vol. 108, Issue 3,
    p405–413. Published online: March 15 2015
viVI
en_AUEN viVI